secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2023-03-27T23:59:59+00:00
Accession:  0000950170-23-010000
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Pharma reports FY2022 net loss $60.3M; cash $283.1M to fund operations into 2026
--------------------------------------------------------------------------------

- Net loss $60.3M for 2022 vs $50.2M in 2021; diluted EPS $1.67 vs $2.21.
- Cash, equivalents and marketable securities $283.1M at Dec 31, 2022; expected runway into 2026.
- R&D expenses $39.6M in 2022, up from $31.3M; G&A $22.4M vs $19.5M.
- Emil Kuriakose to join as CMO oncology in May 2023; Jason Lettiere joined as VP business Dev Nov 2022.
- Phase 2a DUET NASH data expected Q3 2023; key CML and obesity readouts in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023010000/0000950170-23-010000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017023010000/tern-20230327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer